Physician profile
Eunice E Kim
NPI 1043684863
$1,510.52
in general payments reported to CMS, 2019-2025
28 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $795 · 2022: $279 · 2023: $121 · 2024: $177 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $291.18 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $123.79 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $114.00 | 2025 | Clear+Brilliant |
| Emd Serono, INC. | $79.65 | 2021 | |
| Edwards Lifesciences Corporation | $78.84 | 2023-2025 | Sapien 3 Ultra Resilia |
| Ipsen Biopharmaceuticals, INC | $67.12 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.98 | 2021 | |
| Emmaus Medical, INC. | $62.61 | 2021 | |
| Abiomed | $52.16 | 2022-2023 | Impella |
| Abbvie INC. | $51.17 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $44.86 | 2021 | |
| Dova Pharmaceuticals | $41.41 | 2021 | |
| Daiichi Sankyo INC. | $40.66 | 2021 | |
| Eisai INC. | $39.75 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $39.03 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $35.53 | 2021 | |
| Blueprint Medicines Corporation | $31.03 | 2021 | |
| Eusa Pharma (US) LLC | $29.45 | 2021 | |
| Boston Scientific Corporation | $28.41 | 2023 | |
| Glaxosmithkline, LLC. | $27.93 | 2021 | |
| Coherus Oncology, INC. | $27.31 | 2021 | |
| Acceleron Pharma, INC. | $24.99 | 2021 | |
| Celgene Corporation | $24.15 | 2021 | |
| Myovant Sciences INC. | $23.77 | 2021 | |
| Astellas Pharma US INC | $20.69 | 2021 | |
| Taiho Oncology, INC. | $19.79 | 2021 | |
| Janssen Biotech, INC. | $14.44 | 2021 | |
| Deciphera Pharmaceuticals INC. | $13.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunice Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.